Salarius Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7625
- Today's High:
- $0.869
- Open Price:
- $0.81
- 52W Low:
- $0.605
- 52W High:
- $7.195
- Prev. Close:
- $0.84
- Volume:
- 14261
Company Statistics
- Market Cap.:
- $3.06 million
- Book Value:
- 2.51
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-15836828
- Profit Margin:
- 0%
- Return on Assets TTM:
- -58.77%
- Return on Equity TTM:
- -152.67%
Company Profile
Salarius Pharmaceuticals Inc had its IPO on 2015-01-29 under the ticker symbol SLRX.
The company operates in the Healthcare sector and Biotechnology industry. Salarius Pharmaceuticals Inc has a staff strength of 12 employees.
Stock update
Shares of Salarius Pharmaceuticals Inc opened at $0.81 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.76 - $0.87, and closed at $0.8.
This is a -4.75% slip from the previous day's closing price.
A total volume of 14,261 shares were traded at the close of the day’s session.
In the last one week, shares of Salarius Pharmaceuticals Inc have slipped by -9.59%.
Salarius Pharmaceuticals Inc's Key Ratios
Salarius Pharmaceuticals Inc has a market cap of $3.06 million, indicating a price to book ratio of 0.2523 and a price to sales ratio of 18.1198.
In the last 12-months Salarius Pharmaceuticals Inc’s revenue was $0 with a gross profit of $-15836828 and an EBITDA of $-21485418. The EBITDA ratio measures Salarius Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Salarius Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -58.77% with a return of equity of -152.67%.
In Q2, Salarius Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Salarius Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-12.61 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Salarius Pharmaceuticals Inc’s profitability.
Salarius Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.1368 and a EV to EBITDA ratio of 1.5621. Its price to sales ratio in the trailing 12-months stood at 18.1198.
Salarius Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $12.06 million
- Total Liabilities
- $3.64 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Salarius Pharmaceuticals Inc ended 2024 with $12.06 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.06 million while shareholder equity stood at $8.41 million.
Salarius Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $3.64 million in other current liabilities, 335.00 in common stock, $-73023229.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.54 million and cash and short-term investments were $11.54 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Salarius Pharmaceuticals Inc’s total current assets stands at $11.96 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $130000.00 compared to accounts payable of $2.29 million and inventory worth $110409.00.
In 2024, Salarius Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Salarius Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.8
- 52-Week High
- $7.195
- 52-Week Low
- $0.605
- Analyst Target Price
- $3.13
Salarius Pharmaceuticals Inc stock is currently trading at $0.8 per share. It touched a 52-week high of $7.195 and a 52-week low of $7.195. Analysts tracking the stock have a 12-month average target price of $3.13.
Its 50-day moving average was $0.96 and 200-day moving average was $1.63 The short ratio stood at 0.17 indicating a short percent outstanding of 0%.
Around 611.8% of the company’s stock are held by insiders while 645.2% are held by institutions.
Frequently Asked Questions About Salarius Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.